Chosa Oncology is a Danish-Swedish biotechnology company. The company has developed the iCIP platform, which includes a liposomal formulation of cisplatin (LiPlaCis) and the diagnostic tool (DRP) that identifies patients who should benefit most from cisplatin treatment. The achieved clinical phase 2b results mean that the company is ramping up business development to find partners for partnerships or commercial agreements.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Buhl Krone Holding ApS | 20,42 | 20,42 | 2025-09-26 |
| Claus Frisenberg Pedersen | 11,68 | 11,68 | 2023-01-18 |
| IPO Nordic Fund A/S | 7,52 | 7,52 | 2025-09-26 |
| Smerud Medical Research International AS | 6,72 | 6,72 | 2025-09-26 |
| Rutger Arnhult | 4,93 | 4,93 | 2025-09-26 |
| Nels Holding Aps | 4,23 | 4,23 | 2025-09-26 |
| Lh|Lh Invest Aps | 2,67 | 2,67 | 2025-09-26 |
| Karsgaard Holding Ostervra Aps | 2,45 | 2,45 | 2025-09-26 |
| Sorgenfri Nr. 1 A/S | 2,43 | 2,43 | 2025-09-26 |
| Xiaoliang Wu | 2,25 | 2,25 | 2025-09-26 |
2025-11-13 Delårsrapport 2025-Q3
2026-02-26 Bokslutskommuniké 2025
2026-05-27 Årsstämma 2025
